SHS-009

N/A

Report date: 2026/02/06 20:01:23

Base Information

Drug NameSHS-009
Drug Alias NameSHS-009SH009SH-009
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitorsProgrammed death-ligand 1 blockers
TargetsCluster of differentiation 47Programmed death-ligand 1
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLiver Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Sanhome Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Sanhome Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLiver Neoplasms +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A